These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21039539)

  • 1. Factors affecting crystallization of hydrates.
    Tian F; Qu H; Zimmermann A; Munk T; Jørgensen AC; Rantanen J
    J Pharm Pharmacol; 2010 Nov; 62(11):1534-46. PubMed ID: 21039539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium-throughput hydrate screening using the Crystal 16™.
    Sistla A; Wu Y; Khamphavong P; Liu J
    Pharm Dev Technol; 2011 Apr; 16(2):102-9. PubMed ID: 20088649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding.
    Karki S; Friscić T; Jones W; Motherwell WD
    Mol Pharm; 2007; 4(3):347-54. PubMed ID: 17497885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of salt screening methodologies.
    Fernández Casares A; Nap WM; Ten Figás G; Huizenga P; Groot R; Hoffmann M
    J Pharm Pharmacol; 2015 Jun; 67(6):812-22. PubMed ID: 25683791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the maximal solubility advantage of drug salts.
    Skrdla PJ
    Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database.
    Haynes DA; Jones W; Samuel Motherwell WD
    J Pharm Sci; 2005 Oct; 94(10):2111-20. PubMed ID: 16136575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients.
    Bhatt PM; Ravindra NV; Banerjee R; Desiraju GR
    Chem Commun (Camb); 2005 Feb; (8):1073-5. PubMed ID: 15719120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
    David SE; Timmins P; Conway BR
    Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
    Tarsa PB; Towler CS; Woollam G; Berghausen J
    Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
    Healy AM; Worku ZA; Kumar D; Madi AM
    Adv Drug Deliv Rev; 2017 Aug; 117():25-46. PubMed ID: 28342786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effective volumes of waters of crystallization: non-ionic pharmaceutical systems.
    Glasser L
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2019 Oct; 75(Pt 5):784-787. PubMed ID: 32830757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the causes of cocrystal dissociation at high humidity.
    Eddleston MD; Thakuria R; Aldous BJ; Jones W
    J Pharm Sci; 2014 Sep; 103(9):2859-2864. PubMed ID: 24481664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
    Paulekuhn GS; Dressman JB; Saal C
    J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical cocrystals and poorly soluble drugs.
    Thakuria R; Delori A; Jones W; Lipert MP; Roy L; Rodríguez-Hornedo N
    Int J Pharm; 2013 Aug; 453(1):101-25. PubMed ID: 23207015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of hydrate-screening methods.
    Cui Y; Yao E
    J Pharm Sci; 2008 Jul; 97(7):2730-44. PubMed ID: 17914731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallization of a polymorphic hydrate system.
    Tian F; Qu H; Louhi-Kultanen M; Rantanen J
    J Pharm Sci; 2010 Feb; 99(2):753-63. PubMed ID: 19569226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.